Skip to main content
Premium Trial:

Request an Annual Quote

Codex DNA Partners With RNAimmune on mRNA Synthesis Technologies

NEW YORK — Codex DNA has partnered with biopharmaceutical firm RNAimmune on the development of new mRNA synthesis kits, the companies said on Monday.

Under the terms of the deal, RNAimmune will evaluate and validate technologies for automated mRNA synthesis and delivery under development at San Diego-based Codex DNA.

Additional terms were not disclosed.

"Our partnership with Codex DNA can enhance their highly automated solutions for mRNA production," Dong Shen, RNAimmune's founder and president, said in a statement. "Together, we can incorporate our proprietary carrier molecules into Codex DNA's mRNA synthesis kits to improve automated production toward truly transfection-ready mRNA with enhanced uptake and expression."

Newly public Codex DNA, which develops benchtop synthetic biology systems, said that its mRNA synthesis technologies are expected to help in the discovery and development of new mRNA vaccines and therapeutics.

"We look forward to working with the RNAimmune team to validate our highly functional mRNA synthesis kits and potentially integrate RNAimmune's proprietary mRNA delivery solutions into our automated workflows," Codex DNA CEO Todd Nelson said in the statement.

The Scan

Call for a Different Tack

Experts weigh the value of recent experiments testing genetically modified pig kidneys using brain-dead individuals, according to Nature News.

Wastewater Warning

The New York Times reports that wastewater surveillance in some parts of the US point to a possible surge.

Can't Get in the Program

Due to the Northern Ireland protocol dispute, the European Union is preventing UK researchers from joining the Horizon Europe research program, the Times of London reports.

Science Paper on Spatial-Controlled Genome Editing

In Science this week: approach to enable a CRISPR-Cas13a-based system to be used as a cancer therapy.